We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

SYMBICORT® in the Treatment of COPD (SRP COPD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00564499
First Posted: November 28, 2007
Last Update Posted: January 28, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Condition
COPD

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners

Further study details as provided by AstraZeneca:

Study Start Date: March 2006
Study Completion Date: May 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients
Criteria

Inclusion Criteria:

  • patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria:

  • patients who recently quit smoking (<3months)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00564499


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: E Louis, PR Université Libre de Liège
  More Information

ClinicalTrials.gov Identifier: NCT00564499     History of Changes
Other Study ID Numbers: SRP-RB-COPD-2005/1
First Submitted: November 26, 2007
First Posted: November 28, 2007
Last Update Posted: January 28, 2011
Last Verified: January 2011

Keywords provided by AstraZeneca:
COPD
Symbicort
General Practitioners

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents